Cytodrox 500mg Capsule 10’S

INTRODUCTION

CYTODROX 500MG contains Hydroxyurea which belongs to the group of medicines called antineoplastic agents. It is indicated for the treatment of resistant chronic myelocytic leukemia (blood cell cancer), ovarian cancer and skin cancer (melanoma). It can also be used to treat locally advanced squamous cell carcinomas of head and neck in combination with chemoradiation.

Inside the cells, hydroxyurea causes an immediate inhibition of DNA synthesis by inhibiting the enzyme ribonucleotide reductase and produces cell death in S phase. Your doctor will decide the correct dose for you depending upon your condition. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.

The most common side effects are nausea, vomiting, loss of appetite and constipation. Hydroxyurea may harm an unborn baby. Both women and men using this medicine should use birth control to prevent pregnancy, because the use of this medicine by either parent may cause birth defects. Before taking this medicine, inform your doctor if you have any marked bone marrow depression, severe anemia, liver or kidney disease.

USES OF CYTODROX 500MG

• Resistant chronic myelocytic leukemia
• Ovarian cancer
• Melanoma (skin cancer)
• Locally advanced squamous cell carcinomas of head and neck

HOW CYTODROX 500MG WORKS

Following oral administration, hydroxyurea is converted to free radical nitroxide (NO) and enters into the cells, which inactivates the enzyme ribonucleotide reductase. Inactivation of this enzyme causes an immediate inhibition of DNA synthesis and produces cell death in S phase.

DIRECTIONS FOR USE

Take CYTODROX 500MG as directed by your physician. Swallow the medicine with a glass of water. Do not crush or chew the medicine. Your doctor will decide the correct dose for you depending upon your condition. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.

SIDE EFFECTS OF CYTODROX 500MG

HOW TO MANAGE SIDE EFFECTS

Nausea or vomiting:

Try taking this medicine with, or just after meal. Stick to simple meals. Do not eat rich or spicy food.

Constipation: 

Eat fibre rich foods like fresh fruit, vegetables and cereals. Drink plenty of water. Exercise more regularly.

Diarrhea:

Drink lots of fluids, such as water or juice, to avoid dehydration. Do not take any medicines without speaking to a doctor.

WARNING & PRECAUTIONS

INTERACTIONS

Talk to your doctor, if you are taking,

• Other myelosuppressive agents (anti-cancer medicines) e.g. peginterferon alpga-2A, rituximab, alentuzumab
• Live viral vaccine (varicella vaccine, MMR vaccine)
• Antiretroviral Drugs (used to treat HIV) e.g. abacavir, didanosine, zidovudine

SYNOPSIS

MORE INFORMATION

Store below 20-25°C and keep out of reach of children.

FAQs ABOUT CYTODROX 500MG

Can CYTODROX 500MG cause liver damage?

Yes. It may cause liver damage in some individuals. Check with your doctor.

Can CYTODROX 500MG be used during pregnancy?

No. It may harm an unborn baby. It is not recommended for use in pregnancy.

REFERENCES

1. KD. Tripathi. Anticancer drugs. Essentials of medical pharmacology. Seventh edition. 2013. Page – 868.

2. Bruce A. Chabner, Joseph Bertino, James Cleary, Taylor Ortiz, Andrew Lane, Jeffery G. Supko and David Ryan. Cytotoxic agents. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1721-1722.

3. James L. Zehnder. Agents Used in Cytopenias; Hematopoietic Growth Factors. Basic and Clinical Pharmacology. 14th Edition. New York McGarw Hill Education 2018.  Page – 592.

4. Gerald G. Briggs and Roger K. Freeman. H. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 1903-1908.

5. University of Leipzig. Treatment of CML Patients with Imatinib and Hydroxyurea (CML2004) (CML2004). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on June 2015] [Accessed 27th November 2020] https://clinicaltrials.gov/ct2/show/NCT02480608

6. Parveen Jain, V. N. R. Das, Alok Ranjan, Rahul Chaudhary and Krishna Pandey. Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea. NCBI; PMC US National Library of Medicine, National Institute of Health. October-December 2013. [Accessed 27th November 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076923/

7. Bristol-Myers Squibb Company. U.S. Food & Drug Administration. [Revised on March 2016] [Accessed 27th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/016295Orig1s047,s048Lbl.pdf

8. Bristol-Myers Squibb Company. shijiebiaopin.net. [Revised on April 2010] [Accessed 27th November 2020] http://www.shijiebiaopin.net/upload/product/201072222570216.pdf

USEFUL DIAGNOSTIC TESTS

• Biopsy
• Computerized tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Positron emission tomography (PET) scan